euro adhoc: november AG
other
IBL reaches agreement
Subsidiary of november AG goes to Meddens Diagnostic BV
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
Contracts
28.07.2008
IBL Gesellschaft für Immunchemie und Immunbiologie mbH, a 100% subsidiary of november AG, Erlangen, is sold to Meddens Diagnistics BV, Amsterdam in an asset deal transaction. IBL had filed for insolvency last year. The transaction is to be concluded in the next month.
end of announcement euro adhoc
Further inquiry note:
Marcus Weichert
Leitung PR/IR
Telefon: +49(0)9131 75088 868
E-Mail: weichert@november.de
Branche: Biotechnology
ISIN: DE000A0S9N72
WKN: A0S9N7
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade